Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Goals
Fat LossMuscle BuildingInjury HealingAnti-AgingCognitive EnhancementSleep OptimizationImmune SupportGut HealingSkin RejuvenationSexual Health
Peptides
Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PNC-27
Cancer Research
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 32
Back to Home

Peptide Comparison

CrystagenvsPalmitoyl Pentapeptide-4 (Matrixyl)

Immunogeroprotective tripeptide bioregulator (Glu-Asp-Pro) that optimally stimulates thymic epithelial cell proliferation at 200 ng/mL, suppresses thymocyte apoptosis through p53 downregulation and Ki-67 upregulation, and contributed to a 4.1-fold mortality reduction in a 266-person 6-8 year clinical study when combined with complementary pineal peptides

Collagen-boosting signal peptide clinically proven to reduce wrinkles and fine lines in photoaged skin.

ImmuneCosmetic

At a Glance

Quick
comparison

Dose Range

Crystagen

1–100 mcg/kg

Palmitoyl Pentapeptide-4 (Matrixyl)

3 ppm–100 ppm mg

Frequency

Crystagen

Once daily

Palmitoyl Pentapeptide-4 (Matrixyl)

Once daily

Administration

Crystagen

Subcutaneous injection

Palmitoyl Pentapeptide-4 (Matrixyl)

Topical

Cycle Length

Crystagen

8-12 weeks

Palmitoyl Pentapeptide-4 (Matrixyl)

Ongoing/indefinite

Onset Speed

Crystagen

Gradual (3-4 weeks)

Palmitoyl Pentapeptide-4 (Matrixyl)

Moderate (1-2 weeks)

Evidence Level

Crystagen

Limited human trials

Palmitoyl Pentapeptide-4 (Matrixyl)

Limited human trials

Efficacy

Benefit
ratings

Crystagen
Palmitoyl Pentapeptide-4 (Matrixyl)

Immune Rejuvenation

Crystagen94%
Palmitoyl Pentapeptide-4 (Matrixyl)0%

Healthy Aging

Crystagen91%
Palmitoyl Pentapeptide-4 (Matrixyl)0%

Cancer Defense

Crystagen85%
Palmitoyl Pentapeptide-4 (Matrixyl)0%

Anti-Wrinkle

Crystagen0%
Palmitoyl Pentapeptide-4 (Matrixyl)82%

Collagen Production

Crystagen0%
Palmitoyl Pentapeptide-4 (Matrixyl)88%

Skin Rejuvenation

Crystagen0%
Palmitoyl Pentapeptide-4 (Matrixyl)80%

Technical Data

Compound
specifications

Crystagen

Molecular Formula

C14H21N3O8

Molecular Weight

359.3 g/mol

Half-Life

Short plasma half-life typical of tripeptides (minutes); biological effects persist for weeks to months through gene expression modifications and thymic microenvironment restoration; metabolized to constituent amino acids

Bioavailability

Absorbed via intestinal peptide transporters (PepT1/POT and LAT carrier families) when administered orally; rapid absorption from subcutaneous injection sites; efficient cellular uptake due to ultra-short tripeptide structure

CAS Number

Not assigned (patented as immunogeroprotective peptide, US8057810B2)

Palmitoyl Pentapeptide-4 (Matrixyl)

Molecular Formula

C39H75N7O10

Molecular Weight

802.1 Da

Half-Life

Approximately 20-30 minutes in skin (rapidly degraded by aminopeptidases; palmitoylation improves stability vs unmodified KTTKS)

Bioavailability

Topical penetration through stratum corneum to dermis; detected at 4.2 µg/cm² in SC, 2.8 µg/cm² in epidermis, 0.3 µg/cm² in dermis

CAS Number

214047-00-4

Protocols

Dosing
tiers

Crystagen

starting

0.01-1 mcg/kg subcutaneously once daily

Once daily

5 days initial assessment

Conservative protocol based on patent-specified dosing range (0.01-100 μg/kg). Ultra-low doses are effective because Crystagen operates through signal transduction rather than mass-dependent pharmacology. Reconstitute in bacteriostatic water. Administer subcutaneously. Effects are gradual — thymic epithelial rejuvenation and T-cell maturation build over the treatment course.

standard

5-50 mcg/kg subcutaneously once daily

Once daily or 5 consecutive days per month

5-10 days per treatment course

Standard Khavinson protocol. Can be administered as 5-10 consecutive daily injections per course, or as 5 consecutive days monthly for sustained maintenance. The therapeutic window is extremely wide — therapeutic index exceeds 1000x. Repeat courses every 3-6 months. Can be combined with Epithalon for the synergistic thymic-pineal combination that produced 4.1-fold mortality reduction in clinical study.

advanced

50-100 mcg/kg subcutaneously once daily

Once daily or 5 days weekly for extended courses

10-30 days per course or ongoing monthly cycles

Extended protocol for significant immune compromise. Animal longevity studies used 5 days/week for 12+ months with remarkable safety and efficacy. Often combined with Epithalon for comprehensive thymic-pineal anti-aging support. Medical supervision recommended for advanced protocols. The landmark clinical study used annual peptide courses over 6-8 years.

Palmitoyl Pentapeptide-4 (Matrixyl)

Applications

Best
suited for

Crystagen

Restoring thymic function and immune competence in aging individuals with immune senescence

Crystagen is particularly well-suited for individuals focused on restoring thymic function and immune competence in aging individuals with immune senescence. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Comprehensive Khavinson bioregulator protocols for immune and anti-aging support

Crystagen is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols for immune and anti-aging support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Supporting immune function during and after illness recovery

Crystagen is particularly well-suited for individuals focused on supporting immune function during and after illness recovery. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Geroprotective immunomodulation to extend healthspan and reduce age-related disease incidence

Crystagen is particularly well-suited for individuals focused on geroprotective immunomodulation to extend healthspan and reduce age-related disease incidence. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Palmitoyl Pentapeptide-4 (Matrixyl)

Individuals seeking non-invasive anti-wrinkle treatment

Palmitoyl Pentapeptide-4 (Matrixyl) is particularly well-suited for individuals focused on individuals seeking non-invasive anti-wrinkle treatment. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Those with photoaged skin showing fine lines and loss of firmness

Palmitoyl Pentapeptide-4 (Matrixyl) is particularly well-suited for individuals focused on those with photoaged skin showing fine lines and loss of firmness. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

People looking to boost collagen production through topical skincare

Palmitoyl Pentapeptide-4 (Matrixyl) is particularly well-suited for individuals focused on people looking to boost collagen production through topical skincare. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Sensitive skin types seeking well-tolerated anti-aging actives

Palmitoyl Pentapeptide-4 (Matrixyl) is particularly well-suited for individuals focused on sensitive skin types seeking well-tolerated anti-aging actives. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety Profile

Side
effects

Crystagen

Common

  • Injection site reaction
  • Mild fatigue
  • Mild headache
  • Minor digestive changes

Uncommon

  • Flu-like symptoms

Serious

  • No documented serious adverse effects

Palmitoyl Pentapeptide-4 (Matrixyl)

Common

  • Mild Tingling
  • Transient Redness
  • Dryness with Exfoliants
  • Mild Irritation

Uncommon

  • Contact Dermatitis

Serious

  • Excessive Collagen Synthesis and Scar Risk

Research Status

Safety
& evidence

Crystagen

Evidence Level

Limited human trials

FDA Status

Research compound

Safety Overview

Crystagen is a crystalline protein extract (likely containing collagen-derived peptides) from animal tissues that is not FDA-approved and has essentially no published safety data in medical literature. As an undefined and poorly characterized biological mixture, batch consistency, sterility, and identity cannot be verified. Potential risks include allergic reactions to animal proteins, contamination from source tissues, and unknown immunological effects. No formal safety assessments, animal studies, toxicology screening, or human clinical trials exist. The product appears to exist primarily in Russian medical markets, and little information about its actual composition or manufacturing is publicly available.

Contraindications

  • xKnown hypersensitivity to peptide bioregulators or constituent amino acids (glutamic acid, aspartic acid, proline)
  • xPregnancy and breastfeeding — insufficient reproductive safety data
  • xActive autoimmune disease in flare without physician supervision
  • xOrgan transplant recipients on immunosuppression — potential interference with immunosuppressive regimens

Palmitoyl Pentapeptide-4 (Matrixyl)

Evidence Level

Limited human trials

FDA Status

Research compound

Safety Overview

Palmitoyl pentapeptide-4 (Matrixyl) demonstrates excellent dermatological safety with GRAS/safe-for-cosmetic status; extensively used in anti-aging skincare for 20+ years with no serious adverse events. Skin irritation potential is minimal at recommended 2-3% concentrations (irritation index <0.5). No systemic absorption via intact skin; confined to epidermis/dermis per Franz diffusion cell studies. Stability in formulations verified through HPLC analysis.

Contraindications

  • xKnown hypersensitivity to palmitoyl pentapeptide-4 or formulation excipients
  • xActive skin infections at the application site
  • xSeverely compromised skin barrier with open wounds
  • xNo known systemic contraindications at cosmetic concentrations

Decision Guide

Which is
right for you?

Choose Crystagen if...

  • Restoring thymic function and immune competence in aging individuals with immune senescence
  • Comprehensive Khavinson bioregulator protocols for immune and anti-aging support
  • Supporting immune function during and after illness recovery
  • Geroprotective immunomodulation to extend healthspan and reduce age-related disease incidence

Choose Palmitoyl Pentapeptide-4 (Matrixyl) if...

  • Individuals seeking non-invasive anti-wrinkle treatment
  • Those with photoaged skin showing fine lines and loss of firmness
  • People looking to boost collagen production through topical skincare
  • Sensitive skin types seeking well-tolerated anti-aging actives
Peptide ProCrystagen vs Palmitoyl Pentapeptide-4 (Matrixyl) — Peptide Comparison | Peptide Initiative